Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Neuropsychopharmacology Reports is Scopus-indexed (Q2, CiteScore 2.9), WoS ESCI, DOAJ. Published by John Wiley & Sons Inc..
Checked against the index lists dated .
ISSN 2574-173XVerify ISSN ↗
Publisher: John Wiley & Sons Inc.
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Clinical Psychology | 146 / 314 | 53rd | Q2 |
| Psychiatry and Mental Health | 309 / 580 | 46th | Q3 |
| Pharmacology (medical) | 163 / 278 | 41st | Q3 |
| Pharmacology | 215 / 328 | 34th | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2018–present, best quartile Q2, CiteScore 2.9.
Neuropsychopharmacology Reports is Q2 in Clinical Psychology (rank 146 of 314), Q3 in Psychiatry and Mental Health (rank 309 of 580) and Q3 in Pharmacology (medical) (rank 163 of 278), by CiteScore 2025. It is ranked in 4 subject areas in all.
Neuropsychopharmacology Reports is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 2.9, which places it in quartile Q2 at the 53rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.561, quartile Q2, with an H-index of 27.
The publisher lists an article processing charge of about US$2,500 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Neuropsychopharmacology Reports is published by John Wiley & Sons Inc. Its ISSN is 2574-173X.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Neuropsychopharmacology Reports has an h-index of 31 and a 2-year mean of 2.46 citations per paper (OpenAlex). Its Scopus CiteScore is 2.9, quartile Q2. On 2-year citations it ranks #56 of 308 Scopus journals in Clinical Psychology.
Neuropsychopharmacology Reports published 105 papers in 2025; its busiest recent year was 2024 with 112. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 95 research articles (2025–2026), authors are most often from Japan (85.1%), Iran (4.2%) and United Kingdom (3.2%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 5 retracted papers are recorded (6.8 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.